New vistas in malignant mesothelioma: MicroRNA architecture and NRF2/MAPK signal transduction

Gandhi, Manav; Nair, Sreejayan

doi:10.1016/j.lfs.2020.118123

Cited by 14 publications

(11 citation statements)

References 141 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One way to achieve this is by identifying commonly mutated genes which renders a population more susceptible to aid early diagnosis and prognosis of MM. For example, BAP1 is a common germline mutation with high incidences of malignant mesothelioma as we have noted earlier [15] . Similarly, single nucleotide polymorphisms in specific genes can also adversely affect the risk and severity of cancer in different subpopulations with varying ethnicities as we have observed previously for testicular cancer [16] .…”

Section: Introductionsupporting

confidence: 53%

Current perspectives on interethnic variability in multiple myeloma: Single cell technology, population pharmacogenetics and molecular signal transduction

Gandhi¹,

Bakhai²,

Trivedi³

et al. 2022

Translational Oncology

Self Cite

View full text Add to dashboard Cite

Section: Introductionsupporting

confidence: 53%

Current perspectives on interethnic variability in multiple myeloma: Single cell technology, population pharmacogenetics and molecular signal transduction

Gandhi¹,

Bakhai²,

Trivedi³

et al. 2022

Translational Oncology

Self Cite

View full text Add to dashboard Cite

“…We have recently elucidated the non-coding RNA interactome including miRNA networks in cancer chemoprevention (Shah et al, 2021). We have also previously delineated the architecture of miRNA networks in mesothelioma (Gandhi and Nair, 2020), prostate adenocarcinoma (Nair et al, 2014;Nair and Kong, 2015a), cancer chemoprevention (Neelakandan et al, 2012;Nair and Kong, 2015b), as well as miRNA-lncRNA interactions (Nair, 2016). The term miRNA interactome includes cellular biomolecules, e.g., nucleic acids and proteins that interact with miRNA.…”

Section: Introductionmentioning

confidence: 99%

New Vistas in microRNA Regulatory Interactome in Neuropathic Pain

Gada¹,

Pandey²,

Jadhav³

et al. 2022

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

Neuropathic pain is a chronic pain condition seen in patients with diabetic neuropathy, cancer chemotherapy-induced neuropathy, idiopathic neuropathy as well as other diseases affecting the nervous system. Only a small percentage of people with neuropathic pain benefit from current medications. The complexity of the disease, poor identification/lack of diagnostic and prognostic markers limit current strategies for the management of neuropathic pain. Multiple genes and pathways involved in human diseases can be regulated by microRNA (miRNA) which are small non-coding RNA. Several miRNAs are found to be dysregulated in neuropathic pain. These miRNAs regulate expression of various genes associated with neuroinflammation and pain, thus, regulating neuropathic pain. Some of these key players include adenylate cyclase (Ac9), toll-like receptor 8 (Tlr8), suppressor of cytokine signaling 3 (Socs3), signal transducer and activator of transcription 3 (Stat3) and RAS p21 protein activator 1 (Rasa1). With advancements in high-throughput technology and better computational power available for research in present-day pharmacology, biomarker discovery has entered a very exciting phase. We dissect the architecture of miRNA biological networks encompassing both human and rodent microRNAs involved in the development of neuropathic pain. We delineate various microRNAs, and their targets, that may likely serve as potential biomarkers for diagnosis, prognosis, and therapeutic intervention in neuropathic pain. miRNAs mediate their effects in neuropathic pain by signal transduction through IRAK/TRAF6, TLR4/NF-κB, TXIP/NLRP3 inflammasome, MAP Kinase, TGFβ and TLR5 signaling pathways. Taken together, the elucidation of the landscape of signature miRNA regulatory networks in neuropathic pain will facilitate the discovery of novel miRNA/target biomarkers for more effective management of neuropathic pain.

show abstract

“…In the present work, TB appeared the least active on non-malignant cell lines MeT-5A, LP-9, and HMC7, showing the highest differential toxicity towards the malignant cells. It could be speculated that this toxicity is related to the deregulation of the above-mentioned pathways in MPM [32,33]. EM is an anti-protozoal alkaloid [34] extracted from the roots of the Psychotria ipecacuanha plant.…”

Section: Discussionmentioning

confidence: 99%

A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma

Dell’Anno

Melani

Martin

et al. 2022

Cancers

View full text Add to dashboard Cite

The lack of effective therapies remains one of the main challenges for malignant pleural mesothelioma (MPM). In this perspective, drug repositioning could accelerate the identification of novel treatments. We screened 1170 FDA-approved drugs on a SV40-immortalized mesothelial (MeT-5A) and five MPM (Mero-14, Mero-25, IST-Mes2, NCI-H28 and MSTO-211H) cell lines. Biological assays were carried out for 41 drugs, showing the highest cytotoxicity and for whom there were a complete lack of published literature in MPM. Cytotoxicity and caspase activation were evaluated with commercially available kits and cell proliferation was assayed using MTT assay and by clonogenic activity with standard protocols. Moreover, the five most effective drugs were further evaluated on patient-derived primary MPM cell lines. The most active molecules were cephalomannine, ouabain, alexidine, thonzonium bromide, and emetine. Except for alexidine, these drugs inhibited the clonogenic ability and caspase activation in all cancer lines tested. The proliferation was inhibited also on an extended panel of cell lines, including primary MPM cells. Thus, we suggest that cephalomannine, ouabain, thonzonium bromide, and emetine could represent novel candidates to be repurposed for improving the arsenal of therapeutic weapons in the fight against MPM.

show abstract

New vistas in malignant mesothelioma: MicroRNA architecture and NRF2/MAPK signal transduction

Cited by 14 publications

References 141 publications

Current perspectives on interethnic variability in multiple myeloma: Single cell technology, population pharmacogenetics and molecular signal transduction

Current perspectives on interethnic variability in multiple myeloma: Single cell technology, population pharmacogenetics and molecular signal transduction

New Vistas in microRNA Regulatory Interactome in Neuropathic Pain

A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma

Contact Info

Product

Resources

About